Pfizer Starts Mid-Stage Trial for Vaccine against Omicron Subvariant
Desk Report
Published: 27 Jul 2022, 06:48 pm
Pfizer and BioNTech start trials of new Omicron-specific jab || Photo: Collected
Pfizer Inc and its German partner BioNTech SE said on Wednesday they had started a mid-stage study of a modified COVID-19 vaccine that targets both the original as well as the BA.2 omicron subvariant.
Pfizer said the vaccine is in an initial proof-of-concept study to gather more data.
Together, the BA.4 and BA.5 subvariants are estimated to make up nearly 95% of the circulating coronavirus variants in the United States for the week ended Jul 23._Reuters